A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity

Bibliográfalaš dieđut
Váldodahkkit:	Mease, PJ, Gladman, DD, Collier, D, Ritchlin, CT, Helliwell, P, Coates, LC, Strand, V, Liu, L, Kricorian, G, Chung, J
Materiálatiipa:	Conference item
Almmustuhtton:	BMJ Publishing Group 2019

Geahča maid

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
Dahkki: Mease, P, et al.
Almmustuhtton: (2018)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
Dahkki: Vibeke Strand, et al.
Almmustuhtton: (2021-04-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2022)

Methotrexate in psoriasis and psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Dahkki: Nash, P, et al.
Almmustuhtton: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2023)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2018)

GRAPPA 2018 project report
Dahkki: Goel, N, et al.
Almmustuhtton: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Atul Deodhar, et al.
Almmustuhtton: (2022-07-01)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Dahkki: Strand, V, et al.
Almmustuhtton: (2022)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
Dahkki: Choy, E, et al.
Almmustuhtton: (2007)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
Dahkki: Ritchlin, CT, et al.
Almmustuhtton: (2023)

Measuring outcomes in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2020)

Classification and outcome measures for psoriatic arthritis
Dahkki: Leung, Y, et al.
Almmustuhtton: (2018)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
Dahkki: Michelle L. M. Mulder, et al.
Almmustuhtton: (2020-02-01)

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Dahkki: Merola, JF, et al.
Almmustuhtton: (2022)

Etanercept (Enbrel) in the treatment of psoriatic arthritis
Dahkki: T V Korotaeva
Almmustuhtton: (2009-12-01)

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2022)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Dahkki: McInnes, IB, et al.
Almmustuhtton: (2023)

Classification and Outcome Measures for Psoriatic Arthritis
Dahkki: Ying Ying Leung, et al.
Almmustuhtton: (2018-09-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
Dahkki: Orbai, A-M, et al.
Almmustuhtton: (2019)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
Dahkki: Leung, YY, et al.
Almmustuhtton: (2020)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Dahkki: Philip J. Mease, et al.
Almmustuhtton: (2023-08-01)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2020)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2022)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
Dahkki: D.D. Gladman
Almmustuhtton: (2011-09-01)

Psoriatic arthritis
Dahkki: FitzGerald, O, et al.
Almmustuhtton: (2021)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2019)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2024)

Should methotrexate have any place in the treatment of psoriatic arthritis?
Dahkki: Ye, W, et al.
Almmustuhtton: (2019)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
Dahkki: Tillett, W, et al.
Almmustuhtton: (2017)

Effect of Monotherapy with Methotrexate, Etanercept and their Combination on the Quality of Life in Children with Early and Late Juvenile Idiopathic Arthritis: A Prospective Study
Dahkki: Anna N. Fetisova, et al.
Almmustuhtton: (2018-10-01)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
Dahkki: Tillett, W, et al.
Almmustuhtton: (2020)

Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
Dahkki: Rattanakaemakorn P, et al.
Almmustuhtton: (2021-05-01)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
Dahkki: Leung, Y-Y, et al.
Almmustuhtton: (2023)

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2024)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Considerations for the definition of remission criteria in psoriatic arthritis
Dahkki: Mease, P, et al.
Almmustuhtton: (2017)